Uni-Bio Science Group

Uni-Bio Science Group Interest Coverage

The Interest Coverage Ratio of Uni-Bio Science Group (690.HK) as of Oct 16, 2026 is 38.70. In the previous year, Interest Coverage Ratio was 133.93 — a change of -71.11% (lower).

Interest Coverage

38.70

YoY

-71.11%

Last updated:

Interest Coverage Ratio of Uni-Bio Science Group is 2024 38.70 . Interest Coverage Ratio of Uni-Bio Science Group was 2023 133.93 . It decreases by -71.11% lower compared to the previous year.

The Uni-Bio Science Group Interest Coverage history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Interest Coverage
Date
Interest Coverage
Jan 1, 2017
-24.38 HKD
Jan 1, 2018
-562.29 HKD
Jan 1, 2019
-1.27 HKD
Jan 1, 2020
-10.01 HKD
Jan 1, 2021
-60.43 HKD
Jan 1, 2022
49.09 HKD
Jan 1, 2023
133.93 HKD
Jan 1, 2024
38.70 HKD
The Uni-Bio Science Group Interest Coverage history
YEARInterest CoverageYoY
38.70-71.11%
133.93+172.85%
49.09-181.23%
-60.43+503.55%
-10.01+687.23%
-1.27-99.77%
-562.29+2,206.62%
-24.38-17.85%
-29.67-82.67%
-171.25+1,559.49%
-10.32—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Uni-Bio Science Group Stock analysis

What does Uni-Bio Science Group do? Uni-Bio Science Group Ltd, listed on the Hong Kong Stock Exchange under ticker 690.HK with ISIN KYG9198H1406, operates in the Health Care sector within the Biotechnology industry. The company, which completed its IPO on November 12, 2001, employs 340 full-time staff. Uni-Bio Science Group functions through four business segments. The In-house Chemical Pharmaceutical Products segment focuses on manufacturing and selling proprietary chemical pharmaceutical products, including the product named Pinapu. The In-house Biological Pharmaceutical Products segment handles the production and distribution of biological pharmaceutical products such as GeneTime and GeneSoft. The In-house Biological Pipeline segment is dedicated to advancing the industrialization of its biological pipeline, featuring products like Uni-E4 and Uni-PTH. The Third-party Pharmaceutical Products segment manages the sales of pharmaceutical products from external suppliers. The company's headquarters location is not publicly specified, and its official website is www.uni-bioscience.com. Uni-Bio Science Group's business model integrates in-house development with third-party product distribution, targeting both chemical and biological pharmaceutical markets. The company's operational structure reflects a diversified approach to pharmaceutical research, development, and commercialization, though specific details about its research pipeline, market reach, or financial performance are not provided in the available information. Uni-Bio Science Group is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Uni-Bio Science Group stock

Interest Coverage Ratio of Uni-Bio Science Group is 38.70 in 2024.

Interest Coverage Ratio of Uni-Bio Science Group changed from 133.93 to 38.70, representing a -71.11% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Interest Coverage Ratio Uni-Bio Science Group since 2006 – with annual values, charts, and detailed analysis.

The Interest Coverage ratio measures a company's ability to pay interest on its debt. Higher ratios indicate greater financial strength and lower default risk.

Interest Coverage = EBIT / Interest Expense

A 'good' varies by industry and company stage. On Eulerpool, you can compare Interest Coverage Ratio's Uni-Bio Science Group with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Uni-Bio Science Group

All Key Metrics — Uni-Bio Science Group